The trial was discontinued following the independent Data Monitoring Committee recommendation after conducting a planned interim analysis. The interim analysis, which identified no safety concerns, showed the study
Acetylcysteine Solution, USP, developed by InnoPharma, is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions including chronic bronchopulmonary disease, acute
The pazopanib demonstrated non-inferiority to sunitinib in terms of progression free survival (PFS) in the head-to-head study. GSK Oncology president Paolo Paoletti said, "There has been limited information
The new software using customized compound libraries associated with different methods will enable scientists and lab technicians to screen hundreds of samples for hundreds of potential contaminants and
The plants to be relocated include a formulation facility in Longquan, Chengdu and a pre-extraction plant which is currently is in the center of Chengdu. The company said
Clade C vaccines are being developed to treat the HIV virus in the developing world. GeoVax board chairman David Dodd said the company will continue to be grateful
The company will use the funds to develop its nutraceuticals pipeline as well as drug candidates derived from nutraceutical active substances for the treatment of metabolic and
The new Irvine facility is the second powder manufacturing facility, which is expected to support and strengthen risk management program, providing an internal back-up supplier for the customers.
The transaction was completed substantially under the original terms, according to which Church & Dwight paid $650m in cash at closing. The purchase price was financed with $400m
Astellas will continue development and commercialization of ASP015K in Japan. ASP015K, an oral, small molecule Janus Kinase inhibitor, is at present in Phase 2b development as a once-daily
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.